US Interventional Cardiology Market to Decline by $500 Million Through 2017
Intravascular Imaging Catheters and Pressure Guidewires to Show Significant Growth, According to Millennium Research Group
TORONTO, Jan. 8, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, declines in procedure volumes in the United States interventional cardiology (IC) market will lead to a long-term contraction. As a result of the procedure volume decline, coupled with increasing cost sensitivity, this market will show a steady contraction from a value of just under $2.5 billion in 2012 to just under $2 billion by 2017. The only segments to see expansion will be intravascular imaging catheters and pressure guidewires.
In recent years, a growing amount of clinical trial data has resulted in an increased focus on the identification of appropriate candidates for percutaneous coronary interventions (PCI), following a period when stenting for coronary lesions was much more common. Concerns surrounding over-stenting and the introduction of prepayment audits for PCIs covered by Medicare by the Centers for Medicare & Medicaid Services (CMS) are increasing the burden of proof necessary to justify revascularization. The increased scrutiny surrounding PCIs is leading physicians to treat fewer questionable or borderline lesions.
In addition, fewer repeat PCI procedures will be performed through 2017, due to the adoption of next-generation stents, which reduce the need for repeat revascularization procedures. All of these changes will result in a significant decline in procedure volumes.
"On the flip side, these concerns over appropriateness and best outcomes are helping to drive the use of intravascular imaging and pressure guidewires to guide interventions and help ensure best outcomes," said MRG Analyst Ian Swanson. "More physicians are adopting fractional flow reserve (FFR) pressure guidewires, which can determine whether a questionable or borderline lesion is physiologically ischemic enough to warrant treatment with a stent. Intravascular ultrasound (IVUS) and, more recently optical coherence tomography (OCT) catheters allow for more accurate stent placement, particularly with drug-eluting stents (DES). As a result, this segment of the IC market will grow at an average annual rate of nine percent through 2017."
Millennium Research Group's US Markets for Interventional Cardiology Devices 2013 report includes unit, procedures, average selling price and revenue information, along with market drivers and limiters and competitive landscape coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices, intravascular imaging catheters and pressure guidewires and coronary atherectomy devices sold in the United States.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Millennium Research Group
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.